[Urotoxicity of enocitabine (BH-AC) and aclarubicin (ACM) in pediatric patients with hematological malignancies].
Fujiwara
F
F
Yoshihara
T
T
Ikushima
S
S
Esumi
N
N
Todo
S
S
Morioka
Y
Y
Imashuku
S
S
Okano
S
S
Hashida
T
T
Ishii
T
T
D015250:Aclarubicin / Q000008:administration & dosage / Q000009:adverse effects; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D006417:Hematuria / Q000139:chemically induced*; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D015337:Multicenter Studies as Topic; D012189:Retrospective Studies
D003561:Cytarabine; D015250:Aclarubicin; C015019:enocitabine